Abstract
Quizartinib has activity and is well tolerated in patients with relapsed or refractory AML.
- ©2013 American Association for Cancer Research.
October 2013
Volume 3, Issue 10
Volume 3, Issue 10
A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML
Jump to section
Advertisement